According to a new study, led by Penn State College of Medicine, eating mushrooms, in addition to such benefits as decreasing the risk of cancer and premature death, may also reduce the risk of developing depression.
For their study, a team of researchers analyzed data on diet and mental health collected from more than 24,000 U.S. adults between 2005 and 2016. The analysis showed that people who ate mushrooms had lower chances to develop depression.
Scientists believe that mushrooms provide this advantage due to the ergothioneine, an antioxidant able to protect against cell and tissue damage in the body.
Lead researcher Djibril Ba, who recently graduated from the epidemiology doctoral program at the College of Medicine, says: “Mushrooms are the highest dietary source of the amino acid ergothioneine – an anti-inflammatory which cannot be synthesized by humans. Having high levels of this may lower the risk of oxidative stress, which could also reduce the symptoms of depression.”
Recent research, completed by researchers from the University of California, U. S., finds that the new drug ibogaine derived from the root of the plant iboga could be a safer way to treat a range of psychiatric disorders, including depression and addictions, as it is neither toxic nor hallucinogenic.
A team of scientists, led by David Olson, an assistant professor of biochemistry and molecular medicine at the said university, identified the parts of the ibogaine molecule that can be responsible for the therapeutic effects and engineered these features into a new molecule called tabernanthalog (NBG).
After this, the researchers tested this new compound in several animal models of addiction and depression. The analysis of the received data showed that TBG reduced alcohol cravings and signs of opiate withdrawal after a single dose.
Lead study author David Olson says: “We’ve been focused on treating one psychiatric disease at a time, but we know that these illnesses overlap. It might be possible to treat multiple diseases with the same drug.”
A new study, published in the journal BMJ Nutrition, Prevention & Health, suggests that probiotics, as well as a combination of prebiotics and probiotics, may help reduce symptoms of depression.
For the study, the researchers reviewed English-language studies published between 2003 and 2019 and included human participants aged 18 years and older, had clinically confirmed anxiety or depression, and received a dietary prebiotic or probiotic intervention.
The authors of the review found that despite all the studies were significantly different, they all clearly demonstrated a positive benefit of a dietary probiotic intervention for the reduction of symptoms of depression. At the same time, they found little evidence that probiotics could reduce symptoms of anxiety.
A new study from Australia, published in the British Journal of Sports Medicine, suggests that doing active yoga may help relieve symptoms of depression in people diagnosed with a mental health condition.
For the study, the researchers conducted a meta-analysis of 13 trials that studied how yoga influences depression symptoms. These trials included people aged over 18 who were diagnosed with a mental health disorder and were engaged in active yoga that included physical movement for at least 50% of the session duration.
Researchers from School of Health Sciences, University of South Australia, write: “For further understanding of the mechanism by which yoga has an effect on mental and physical health, intervention variables, such as type of yoga, intensity, environment, instructor qualification, specific postures, cueing, philosophical focuses, mindfulness techniques, and breathing techniques, should be adequately reported.”
A small preliminary study from Stanford University School of Medicine, US, finds that an intensive course of precisely targeted brain simulation can be a new safe method to relieve depression and prevent suicidal thoughts.
The new treatment is called Stanford Accelerated Intelligent Neuromodulation Therapy, which is shortened to SAINT. With the help of this therapy, the researchers managed to rapidly resolve symptoms of depression in 90% of patients involved in the study.
The scientists conclude in their paper: “The efficacy of SAINT at treating suicidal ideation and the short duration of the protocol suggest SAINT could provide a means of rapidly ensuring the safety of suicidal patients.”
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.